NVDA−4.40%AAPL+1.23%GOOGL−3.15%MSFT−2.23%AMZN−4.57%TSM−4.52%SPCX−9.14%META−6.98%
StockVS

NASDAQ · Biotechnology · USD

Satellos Bioscience Inc. (MSLE) Stock Analysis

Satellos Bioscience Inc. (MSLE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 22, 2026

MSLE

$6.63

−$0.08 (−1.12%)

Oct 22, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MSLE with… →

MSLE Key Statistics

As of Oct 22, 2026
Trading
Open
$6.74
Previous Close
$6.70
Day's Range
6.57–6.95
52-Week Range
5.30–13.40
Volume
21.15K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.15
Valuation
Market Cap
$140.56M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.95
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$24.87M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
21.22M
1-Year Return
+3.00%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
42.27K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 22, 2026, MSLE closed at $6.63, +3.00% over 1 year.

Satellos Bioscience Inc. (MSLE) has a market capitalization of $140.56M.

In fiscal 2025, MSLE reported revenue of $0.00.

MSLE Stock Return by Calendar Year

Satellos Bioscience Inc. (MSLE) 10-year return: what $10,000 became

1 year
$10,000 $10,300
+3.00%
5 years
$10,000 $4,723
−52.77%
10 years
$10,000 $9,519
−4.81%

If you had invested $10,000 in Satellos Bioscience Inc. (MSLE) 10 years ago, at the close on October 21, 2016, it would have been worth $9,519 at the close on October 22, 2026: −4.81% in total, −0.49% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+12.67%
2025−16.95%
2024+81.54%
2023+88.95%
2022−78.77%
2021−17.35%
2020−7.55%
2019+65.63%
2018+6.67%
2017−6.25%
2016 (partial year)−43.86%

As of October 22, 2026.

MSLE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$24.87M—
2024$0.00−$20.63M—
2023$0.00−$11.98M—
2022$0.00−$8.34M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$26.46M−$24.87M—
2024$0.00—−$20.40M−$20.63M—
2023$0.00—−$11.66M−$11.98M—
2022$0.00—−$6.21M−$8.34M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Satellos Bioscience Inc. (MSLE) is capitalised at $140.56M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 18.

The 52-week range on file runs from $5.30 to $13.40. The most recent close on file for MSLE is $6.63, dated October 22, 2026. That is −$0.08 (−1.12%) against the previous close. The latest close sits 24.91% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $24.87M. Earnings per share on a trailing basis come to −1.95.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.15. Annualized volatility over the trailing 10 years is 1,868.79%. Over the trailing twelve months the total return is +3.00%. Across 10 years the annualized return works out at −0.49%.

Growth & Income

The record shows no dividend for MSLE.

So far in 2026 the total return is +12.67%. The strongest complete calendar year on file is 2023 at +88.95%; the weakest is 2022 at −78.77%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Satellos Bioscience Inc. (MSLE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Satellos Bioscience Inc. MSLE $140.56M —
Vertex Pharmaceuticals Incorporated VRTX $135.64B 31.0
Regeneron Pharmaceuticals, Inc. REGN $84.33B 20.3
Moderna, Inc. MRNA $80.90B —

The Biotechnology industry average P/E ratio is 16.6x. Satellos Bioscience Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$135.64B

 REGN

Regeneron Pharmaceuticals, Inc.

$84.33B

 MRNA

Moderna, Inc.

$80.90B

 ARGX

argenx SE

$55.07B

 ONC

BeOne Medicines AG

$43.49B

 RVMD

Revolution Medicines, Inc.

$40.23B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.17T

 JNJ

Johnson & Johnson

$644.91B

 ABBV

AbbVie Inc.

$503.96B

 UNH

UnitedHealth Group Incorporated

$381.46B

 MRK

Merck & Co., Inc.

$363.27B
View all Healthcare stocks →

About Satellos Bioscience Inc.

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Visit website →